

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l., (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

**BUSINESS UPDATE ON PRECLINICAL STUDIES OF CANCER VACCINES  
TARGETING KRAS AND PD-L1 AND THE PROGRESS OF RESEARCH  
COLLABORATION WITH XTALPI**

CK Life Sciences Int'l., (Holdings) Inc. (the “Company”) announces that the Company will present new data from preclinical studies of two investigational cancer vaccines, targeting the KRAS (Kirsten rat sarcoma virus) and PD-L1 (programmed cell death ligand 1) proteins, respectively, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, USA.

The KRAS protein, frequently mutated in various cancers, is a key regulator of cell growth and survival, driving tumor development by promoting uncontrolled cell proliferation and resistance to treatment. The PD-L1 protein represents one of the most important immune checkpoint proteins highly expressed on cancer cells to limit T-cell activation in the tumor microenvironment.

In the preclinical studies, the Company investigated whether multi-peptide cancer vaccines targeting KRAS, and a novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes could induce significant anti-tumor efficacy in a syngeneic mouse colorectal cancer model.

In addition, the Company and its research collaborator, XtalPi, will present data showcasing their Artificial Intelligence (AI)-empowered platform for designing cancer vaccines at the 2024 AACR Annual Meeting. The Company and XtalPi found that AI models developed in their research collaboration significantly improve neoantigen peptide vaccine design, surpassing the performance of state-of-the-art prediction algorithms for both MHC-I and MHC-II antigen presentation.

The Company considers that the preclinical efficacy results of the investigational cancer vaccines targeting KRAS and PD-L1 proteins are promising and the Company hopes to advance these and other vaccines into clinical development in the future. The Company is pleased with the progress made in its research collaboration with XtalPi to develop an AI platform aimed at better predicting immunogenicity and designing cancer vaccines that are more likely to be effective.

**It should be noted that the Company is only at the preclinical study stage and has not yet commenced clinical trials for KRAS and PD-L1 vaccines and accordingly, there is no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**CK Life Sciences Int'l., (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 5 April 2024

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).*